NCT05813314终止1 期
A Phase 1, Randomized, Open-Label, Sponsor-Open, Two-Sequence, Two-Period Crossover Study to Investigate the Bioequivalence of a Single Subcutaneous Dose of BMN 111 Administered Using Either a Vial and Syringe or Injector Pen in Healthy Adult Participants
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 36
- 试验地点
- 1
- 主要终点
- Maximum observed drug concentration (Cmax)
研究概览
简要总结
The purpose of this study is to establish the bioequivalence of a single SC dose of BMN 111 administered using a vial and syringe versus using an injector pen.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Participants must be aged 18 to 55 years inclusive, at the time of signing the informed consent.
- •Participants must be non-smoking (have never smoked, or stopped smoking > 3 months prior to dosing), and can be of any ethnicity.
- •Participants must be healthy as determined by the absence of clinically relevant abnormalities identified by medical evaluation, including medical history, full physical examination, laboratory tests, cardiac monitoring, supine vital signs to include temperature, and assessment of prior and concomitant medications.
- •Body weight ≥ 60 kg and < 110 kg and body mass index within the range 18.0 to 32.0 kg/m2 (inclusive).
- •Males and/or females are eligible to participate in this clinical study.
- •Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
- •Females will not be pregnant or lactating, and females of childbearing potential and males will agree to use contraception.
- •Participants must be capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF).
排除标准
- •Any condition considered to affect drug absorption (eg, conditions affecting SC administration such as reduced SC blood flow, lipohypertrophy, and significantly high/low skin temperature).
- •Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the investigator (or designee).
- •History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless approved by the investigator (or designee).
- •History of migraines.
- •Confirmed (eg, two consecutive measurements) systolic blood pressure > 140 or < 90 mmHg, diastolic blood pressure > 90 or < 50 mmHg, and pulse rate > 100 or < 40 beats per minute or recurrent symptomatic hypotension (defined as episodes of low BP generally accompanied by symptoms e.g., dizziness and fainting) or recurrent symptomatic orthostatic hypotension.
- •Positive hepatitis panel and/or positive human immunodeficiency virus test.
- •Exposure to mycobacterium tuberculosis, indicative of tuberculosis infection, as confirmed by a positive QuantiFERON-TB Gold test.
- •A positive COVID-19 test at Screening or Check-in.
- •Taking any of the prohibited medications.
- •Administration of a coronavirus disease 2019 (COVID-19) vaccine within 30 days prior to dosing.
- •Use or intend to use any medications/products known to alter drug absorption, metabolism, or elimination processes, including St. John's wort, within 30 days prior to dosing, unless deemed acceptable by the investigator (or designee).
- •Use or intend to use any prescription medications/products other than hormone replacement therapy (HRT), oral, implantable, transdermal, injectable, or intrauterine contraceptives within 7 days (or 14 days if the drug is a potential enzyme inducer), or 5 half-lives (whichever is longer), prior to dosing, unless deemed acceptable by the investigator (or designee).
- •Use or intend to use slow release medications/products considered to still be active within 14 days prior to Check-in, unless deemed acceptable by the investigator (or designee).
- •Use or intend to use any nonprescription medications/products including vitamins, minerals, and phytotherapeutic/herbal/plant derived preparations within 7 days, or 5 half-lives (whichever is longer), prior to dosing, unless deemed acceptable by the investigator (or designee).
- •Participation in a clinical study involving administration of an investigational drug (new chemical entity) in the past 30 days or 5 half-lives prior to dosing (whichever is longer).
- •Have previously completed or withdrawn from this study or any other study investigating BMN 111 and have previously received BMN
- •Aspartate aminotransferase, alanine aminotransferase, or bilirubin ≥ 1.5 × upper limit of normal or estimated glomerular filtration rate < 60 mL/min/1.73m2 (Chronic Kidney Disease Epidemiology Collaboration 2021).
- •Receipt of blood products within 2 months prior to Check-in.
- •Donation of blood from 3 months prior to Screening, plasma from 2 weeks prior to Screening, or platelets from 6 weeks prior to Screening.
- •Poor peripheral venous access.
- •Participants who, in the opinion of the investigator (or designee), should not participate in this study.
- •Any skin condition, such as scarring or tattoos, which may preclude receipt of the study drug.
- •Unwilling or unable to comply with scheduled visits, the treatment plan, laboratory tests and other study procedures or lifestyle guidance.
研究组 & 干预措施
BMN 111 injection with vial and syringe
Active Comparator
Study treatment will be provided in glass vials. Each glass vial will be labeled as required per country requirement. Pre-filled Diluent Transfer Syringes will be provided for reconstitution.
干预措施: BMN 111 administration via vial and syringe (Drug)
BMN 111 injection with injector pen
Experimental
Study treatment will be provided in a prefilled injector pen containing a dual chamber drug cartridge, for reconstitution and injection, after setting of the specified dose with the 2.0 mg/mL formulation.
干预措施: BMN 111 administration via Injector Pen (Combination Product)
结局指标
主要结局
Maximum observed drug concentration (Cmax)
时间窗: Predose, 2, 5, 15, 30, 45, 60, and 75 minutes and 1.5, 2, 2.5, 3, 4, 6, and 8 hours postdose
Area under the concentration versus time curve from time 0 to infinity (AUC0-∞)
时间窗: Predose, 2, 5, 15, 30, 45, 60, and 75 minutes and 1.5, 2, 2.5, 3, 4, 6, and 8 hours postdose
Area under the concentration versus time curve from time 0 to t, where t is the last timepoint with a measurable concentration (AUC0-t)
时间窗: Predose, 2, 5, 15, 30, 45, 60, and 75 minutes and 1.5, 2, 2.5, 3, 4, 6, and 8 hours postdose
次要结局
- Time of t1/2(Predose, 2, 5, 15, 30, 45, 60, and 75 minutes and 1.5, 2, 2.5, 3, 4, 6, and 8 hours postdose)
- Incidence and severity of adverse events(2 weeks)
- Time of Cmax (tmax)(Predose, 2, 5, 15, 30, 45, 60, and 75 minutes and 1.5, 2, 2.5, 3, 4, 6, and 8 hours postdose)
- Time of terminal rate constant (λZ)(Predose, 2, 5, 15, 30, 45, 60, and 75 minutes and 1.5, 2, 2.5, 3, 4, 6, and 8 hours postdose)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Study to Determine the Pharmacokinetic (PK) Bioequivalence of ABP 501 and Adalimumab (Humira®) in Healthy Adult Japanese ParticipantsHealthy VolunteersNCT05995691Amgen179
招募中
2 期
A Phase Ⅱa Study of the Safety, Tolerability and Efficacy of BD111 in Herpes Simplex Virus Type I Stromal KeratitisHerpes Simplex Virus Type I Stromal KeratitisNCT06474442Shanghai BDgene Co., Ltd.40
招募中
早期 1 期
Evaluation of the Safety and Efficacy of BBM-D101 to Treat Patients with Duchenne Muscular DystrophyDuchenne Muscular Dystrophy (DMD)NCT06641895Shanghai Jiao Tong University School of Medicine6
已完成
1 期
A Study to Assess the Pharmacokinetics, Immunogenicity and Safety of Escalating Doses of BMS-188667 Given as a Single Intravenous Infusion to Patients With Psoriasis VulgarisPsoriasis VulgarisNCT00277225Bristol-Myers Squibb32
已完成
3 期
Efficacy of BNC210 in Acute, As-needed Treatment of Anxiety in Social Anxiety Disorder - 1Social Anxiety DisorderNCT06510504Bionomics Limited370